The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer
To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of advanced gastric cancer (AGC)
Advanced Gastric Cancer
DRUG: Paclitaxel|DRUG: Oxaliplatin and Capecitabine
Progression Free Survival (PFS), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
overall survival (OS), from the date of randomization until death from any cause or up to 1 year|adverse events (AE), from date of randomization to 28 days after the last chemo dosage|health-related quality of life (HRQOL, evaluate every 6 weeks from the date of randomization until 28 days after the last chemo dosage
To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of advanced gastric cancer (AGC)